Remdesivir as a possible therapeutic option for the COVID-19

Travel Medicine and Infectious Disease

Volumn 34, Issue , 2020, Pages

  Al Tawfiq, Jaffar A ^a,b,c   Al Homoud, Ali H ^a   Memish, Ziad A ^d,e,f  

^a DHAHRAN HEALTH CENTER   (Saudi Arabia)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MINISTRY OF HEALTH   (Saudi Arabia)

^e ALFAISAL UNIVERSITY   (Saudi Arabia)

^f EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; LOPINAVIR; REMDESIVIR; RITONAVIR; RNA POLYMERASE; ADENOSINE PHOSPHATE; ALANINE;

ANTIVIRAL ACTIVITY; CORONAVIRUS DISEASE 2019; DRUG EFFICACY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; HUMAN; LETTER; LOADING DRUG DOSE; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; OXYGEN SATURATION; PRIORITY JOURNAL; SARS CORONAVIRUS; TREATMENT OUTCOME; BETACORONAVIRUS; CORONAVIRUS INFECTION; PANDEMIC; VIRUS PNEUMONIA;

ADENOSINE MONOPHOSPHATE; ALANINE; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85081208593     PISSN: 14778939     EISSN: 18730442     Source Type: Journal    
DOI: 10.1016/j.tmaid.2020.101615     Document Type: Letter

References (13)

1. Baharoon, S., Memish, Z.A., MERS-CoV as an emerging respiratory illness: a review of prevention methods. Trav Med Infect Dis, 32, 2019, 10.1016/j.tmaid.2019.101520.
2. World Health Organization, Situation Report-17 SITUATION IN NUMBERS total and new cases in last 24 hours., 2020 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200206-sitrep-17-ncov.pdf?sfvrsn=17f0dca_2. (Accessed 7 February 2020)
3. Warren, T.K., Jordan, R., Lo, M.K., Ray, A.S., Mackman, R.L., Soloveva, V., et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531 (2016), 381–385, 10.1038/nature17180.
4. Warren, T., Jordan, R., Lo, M., Soloveva, V., Ray, A., Bannister, R., et al. Nucleotide prodrug GS-5734 is a broad-spectrum filovirus inhibitor that provides complete therapeutic protection against the development of Ebola virus disease (EVD) in infected non-human primates. Open Forum Infect Dis, 2, 2015, 10.1093/ofid/ofv130.02.
5. Jacobs, M., Rodger, A., Bell, D.J., Bhagani, S., Cropley, I., Filipe, A., et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 388 (2016), 498–503, 10.1016/S0140-6736(16)30386-5.
6. Mulangu, S., Dodd, L.E., Davey, R.T., Mbaya, O.T., Proschan, M., Mukadi, D., et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 381 (2019), 2293–2303, 10.1056/NEJMoa1910993.
7. Agostini, M.L., Andres, E.L., Sims, A.C., Graham, R.L., Sheahan, T.P., Lu, X., et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio, 9, 2018, 10.1128/mBio.00221-18.
8. Sheahan, T.P., Sims, A.C., Graham, R.L., Menachery, V.D., Gralinski, L.E., Case, J.B., et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med, 9, 2017, 10.1126/scitranslmed.aal3653.
9. Sheahan, T.P., Sims, A.C., Leist, S.R., Schäfer, A., Won, J., Brown, A.J., et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun, 11, 2020, 10.1038/s41467-019-13940-6.
10. Liu, W., Morse, J.S., Lalonde, T., Xu, S., Learning from the past: possible urgent prevention and treatment options for severe Acute respiratory infections caused by 2019‐nCoV. ChemBioChem, 2020, 10.1002/cbic.202000047 cbic.202000047.
11. Holshue, M.L., DeBolt, C., Lindquist, S., Lofy, K.H., Wiesman, J., Bruce, H., et al. First case of 2019 novel coronavirus in the United States. N Engl J Med, 2020, 10.1056/nejmoa2001191.
12. Cao, B., Mild/moderate 2019-nCoV remdesivir RCT - Full Text View - ClinicalTrials.gov. 2020 https://clinicaltrials.gov/ct2/show/NCT04252664. (Accessed 13 February 2020)
13. Cao, B., Severe 2019-nCoV remdesivir RCT - Full Text View - ClinicalTrials.gov. 2020 https://clinicaltrials.gov/ct2/show/NCT04257656. (Accessed 13 February 2020)